Laval, December 1, 2025 – Morphocell Technologies, a biotechnology company developing next-generation tissue therapies for organ replacement, announces the closing of a US$50 million Series A financing round, following a US$10 million addition led by Investissement Québec and CDP Ventures Capital, created by Italy’s Cassa Depositi e Prestiti (CDP).
This extension of financing builds on the initial Series A round of US$40 million completed in February 2024 under the leadership of Genson Capital and marks an important milestone in Morphocell’s mission to transform the treatment of liver disease. The participation of two major institutional investors with long-term impact-focused mandates strengthens the company’s growth base and extends its operational capacity to more than three years.
“Since the initial closing of our Series A financing, Morphocell has made exceptional progress in development, manufacturing, and team expansion. Investissement Québec’s decision to increase its commitment and CDP Ventures Capital’s decision to join our investor coalition are a strong vote of confidence in our vision and execution capabilities. Their support confirms the global impact potential of our tissue therapies and increases our ability to develop and deploy regenerative therapies for liver diseases,” said Dr. Massimiliano Paganelli, CEO and co-founder of Morphocell Technologies.
Following the completion of the Series A financing, Morphocell has grown its workforce to 44 employees, spread across its headquarters in the Greater Montreal area and its offices in Cambridge (Boston) and Toronto. The company operates vertically integrated operations covering discovery, cell manufacturing, and preclinical development, demonstrating its commitment to excellence in the field of regenerative medicine.
A coalition of reputable investors
“After Impulsion PME’s initial support in 2024, we are even more proud to continue our business relationship with Morphocell by reinvesting in its development through the new Impulsion fund and our own capital,” said Bicha Ngo, President and CEO of Investissement Québec. The growing life sciences sector is helping to promote Quebec’s talent and expertise internationally, while enabling the emergence of innovative solutions to multiple health challenges. Investissement Québec is pleased to support Morphocell in achieving its ambitions.”
“We are particularly proud to support Morphocell, an exceptional company founded by Italian doctors and scientists, which perfectly illustrates how Italian talent can innovate and make an impact on an international scale,” said Alessandro Scortecci, Chief Direct Investments at CDP Venture Capital. This is our first investment in a Canadian biotechnology company, a decision motivated by our desire to connect Italy to global innovation ecosystems. This investment enables the establishment of Morphocell’s first European subsidiary in Italy, which will leverage the country’s excellence in talent, research capabilities, and industrial know-how to strengthen the company’s global role in the field of regenerative medicine.”
A forward-looking platform
With the completion of its US$50 million Series A financing round, Morphocell Technologies is now one of the best-funded private regenerative medicine companies in Canada. This funding will enable the company to:
- Advance its lead program, ReLiver®, toward clinical proof of concept;
- Expand its manufacturing capacity and world-class team of experts;
- Deepen its international collaborations and lay the groundwork for its next rounds of financing.
Building on its strong presence in Quebec and North America, Morphocell will now establish its first European subsidiary in Italy, a move that reflects the company’s Italian roots and its commitment to supporting the development of Italy’s rapidly expanding biotechnology sector. This expansion will serve as a strategic gateway to Europe, enabling Morphocell to build partnerships, access a pool of talent and world-class research infrastructure, and consolidate its position as a global leader in regenerative medicine.
“Morphocell’s goal has always been clear: to create revolutionary cell-based organ replacement therapies that heal patients,” adds Dr. Paganelli. “This additional funding also reinforces our shared belief, shared with our investors, partners, and team, that we are building the future of regenerative medicine right here in Quebec.”
“Our government is proud to support Morphocell Technologies in its growth. We want to help stimulate innovation in Quebec, which will play a decisive role in the evolution of modern medicine, particularly in regenerative medicine. This commitment is part of our desire to build a strong, dynamic, and forward-looking ecosystem where our companies can develop promising solutions for the health of tomorrow,” said Christine Fréchette, Minister of Economy, Innovation, and Energy.
